Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.
Authors
Ye Guo
Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China;
Ye Guo , Chunwang Yuan , Weimin Ding , Yi Gao , Xu Zhu , Jieer Ying , Meili Sun , Jingdong Zhang , Zhixiang Zhuang , Yangqing Huang , Lichun Deng , Ping Chen , Yuxian Bai , Zuoxing Niu , Wei Li , Xiaoyu Yin , Aibing Xu , Yufeng Cheng , Jin Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03758664
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 572)
DOI
10.1200/JCO.2023.41.4_suppl.572
Abstract #
572
Poster Bd #
E4
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Indirect treatment comparison of futibatinib with chemotherapy and pemigatinib in cholangiocarcinoma with FGFR2 fusions/rearrangements.
First Author: Mitesh J. Borad
Poster
2019 ASCO Annual Meeting
Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
First Author: Joon Oh Park
Poster
2019 Gastrointestinal Cancers Symposium
Halo 110-101: Early safety results of pegvorhyaluronidase alfa (PEGPH20; PVHA) + cisplatin (C) + gemcitabine (G) ± atezolizumab (ATZ) in patients (pts) with locally advanced or metastatic cholangiocarcinoma (CCA) and gallbladder cancer (GBC).
First Author: Do-Youn Oh
Poster
2018 Gastrointestinal Cancers Symposium
HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic cholangiocarcinoma and gallbladder cancer.
First Author: Mitesh J. Borad